In the phase 3 BRIDGE trial (n = 20), pegunigalsidase alfa slowed progression of kidney disease (mean eGFR slope was −5.90 mL/min/1.73 m2/year with agalsidase alfa compared with −1.19 mL/min/1.73 m2/year 12 months after switching to pegunigalsidase alfa) [139]. This evidence concerns the gene GLA and kidney disorder.